SOLU-CORTEF (hydrocortisone sodium succinate) by Pfizer is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. First approved in 1955.
Drug data last refreshed 11h ago · AI intelligence enriched 11h ago
SOLU-CORTEF is an intravenous glucocorticoid (hydrocortisone sodium succinate) approved since 1955 for rapid delivery of high-dose corticosteroid therapy. It works by suppressing inflammation and modifying immune response across multiple organ systems. The water-soluble formulation enables immediate IV administration for acute, life-threatening inflammatory and adrenocortical conditions requiring rapid therapeutic effect.
As a long-established injectable with LOE approaching, the brand team is likely focused on defending market share and managing generic transition rather than growth initiatives.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on SOLU-CORTEF at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on SOLU-CORTEF offers stability in a mature, essential hospital product with deep institutional relationships, but limited growth upside. Roles emphasize operational efficiency, formulary management, and competitive defense rather than market expansion or product innovation.